Search

Your search keyword '"Antibodies, Monoclonal economics"' showing total 26 results
Start Over Descriptor "Antibodies, Monoclonal economics" Journal bmj clinical research ed
26 results on '"Antibodies, Monoclonal economics"'

1. New preventive treatments for migraine.

Author

Burch R and Rayhill M

Subjects
Antibodies, Monoclonal economics, Antibodies, Monoclonal immunology, Antibodies, Monoclonal, Humanized economics, Antibodies, Monoclonal, Humanized therapeutic use, Calcitonin Gene-Related Peptide immunology, Cost-Benefit Analysis, Drug Costs, Humans, Migraine Disorders economics, Antibodies, Monoclonal therapeutic use, Migraine Disorders prevention & control
Abstract

Competing Interests: Competing interests: We have read and understood BMJ policy on declaration of interests and have no relevant interests to declare.

Published
2018
Full Text
View/download PDF

2. NICE approves immunotherapy combination for advanced melanoma.

Author

Wise J

Subjects
Antibodies, Monoclonal administration & dosage, Antibodies, Monoclonal economics, Antineoplastic Combined Chemotherapy Protocols economics, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Drug Approval, Drug Costs, Humans, Immunotherapy economics, Immunotherapy methods, Ipilimumab, Melanoma economics, Nivolumab, Skin Neoplasms economics, United Kingdom, Melanoma drug therapy, Skin Neoplasms drug therapy
Published
2016
Full Text
View/download PDF

3. New cholesterol drugs are overpriced, independent analysis finds.

Author

McCarthy M

Subjects
Antibodies, Monoclonal administration & dosage, Antibodies, Monoclonal, Humanized, Anticholesteremic Agents administration & dosage, Atherosclerosis prevention & control, Cost-Benefit Analysis, Humans, Antibodies, Monoclonal economics, Anticholesteremic Agents economics, Atherosclerosis drug therapy, Hypercholesterolemia drug therapy
Published
2015
Full Text
View/download PDF

4. Norway backs downs over plan to exclude anticancer drugs from coverage.

Author

Hansen A

Subjects
Androstenes, Androstenols therapeutic use, Antibodies, Monoclonal therapeutic use, Antineoplastic Agents therapeutic use, Humans, Ipilimumab, Norway, Androstenols economics, Antibodies, Monoclonal economics, Antineoplastic Agents economics, Insurance Coverage, Insurance, Pharmaceutical Services economics, National Health Programs organization & administration
Published
2013
Full Text
View/download PDF

5. Optional copayments on anti-cancer drugs.

Author

van de Vooren K, Curto A, and Garattini L

Subjects
Antibodies, Monoclonal economics, Antibodies, Monoclonal, Humanized economics, Bevacizumab, Cetuximab, Cost Control, Cost-Benefit Analysis, Humans, Neoplasms drug therapy, Patient Participation, Antineoplastic Agents economics, Deductibles and Coinsurance, Health Care Costs, Neoplasms economics
Published
2013
Full Text
View/download PDF

8. Cost comparison of ranibizumab and bevacizumab.

Author

Jackson TL and Kirkpatrick L

Subjects
Angiogenesis Inhibitors therapeutic use, Antibodies, Monoclonal therapeutic use, Antibodies, Monoclonal, Humanized therapeutic use, Bevacizumab, Costs and Cost Analysis, Humans, Ranibizumab, United Kingdom, Wet Macular Degeneration drug therapy, Angiogenesis Inhibitors economics, Antibodies, Monoclonal economics, Antibodies, Monoclonal, Humanized economics, Wet Macular Degeneration economics
Published
2011
Full Text
View/download PDF

9. NICE is likely to reject bevacizumab for bowel cancer.

Author

White C

Subjects
Antibodies, Monoclonal economics, Antibodies, Monoclonal, Humanized, Antineoplastic Agents economics, Bevacizumab, England, Wales, Antibodies, Monoclonal therapeutic use, Antineoplastic Agents therapeutic use, Drug Approval legislation & jurisprudence, Intestinal Neoplasms drug therapy
Published
2010
Full Text
View/download PDF

10. Bevacizumab and ranibizumab. Bevacizumab and the inverse postcode lottery.

Author

Harris MJ

Subjects
Aged, Angiogenesis Inhibitors therapeutic use, Antibodies, Monoclonal therapeutic use, Antibodies, Monoclonal, Humanized, Bevacizumab, Drug Costs, Humans, Ranibizumab, Residence Characteristics, State Medicine, United Kingdom, Angiogenesis Inhibitors economics, Antibodies, Monoclonal economics, Macular Degeneration drug therapy
Published
2010
Full Text
View/download PDF

11. Doctors warn against using Avastin for macular degeneration.

Author

Kmietowicz Z

Subjects
Antibodies, Monoclonal economics, Antibodies, Monoclonal therapeutic use, Antibodies, Monoclonal, Humanized, Bevacizumab, Drug Costs, Humans, Macular Degeneration economics, Ophthalmic Solutions economics, Ranibizumab, Risk Factors, United Kingdom, Antibodies, Monoclonal adverse effects, Macular Degeneration drug therapy, Off-Label Use economics, Ophthalmic Solutions adverse effects
Published
2010
Full Text
View/download PDF

12. Patient challenges trust's right to deprive her of NHS treatment for buying drugs privately.

Author

Dyer C

Subjects
Aged, Angiogenesis Inhibitors economics, Antibodies, Monoclonal economics, Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols economics, Bevacizumab, Cisplatin economics, Deoxycytidine analogs & derivatives, Deoxycytidine economics, Female, Humans, State Medicine economics, United Kingdom, Gemcitabine, Patient Acceptance of Health Care, Patient Rights legislation & jurisprudence, Prescription Fees legislation & jurisprudence, State Medicine legislation & jurisprudence
Published
2008
Full Text
View/download PDF

13. The ranibizumab saga of drug profiteering.

Author

Lee AC and Radford J

Subjects
Antibodies, Monoclonal, Humanized, Cost-Benefit Analysis, Drug Costs, Humans, Ranibizumab, United Kingdom, Antibodies, Monoclonal economics, Drug Industry economics, Macular Degeneration drug therapy
Published
2008
Full Text
View/download PDF

14. NICE introduces cost sharing scheme for sight drug.

Author

Dobson R

Subjects
Antibodies, Monoclonal economics, Antibodies, Monoclonal, Humanized, Aptamers, Nucleotide economics, Bevacizumab, Cost Sharing, Drug Costs, Humans, Ranibizumab, Blindness drug therapy, Ophthalmic Solutions economics
Published
2008
Full Text
View/download PDF

15. Watchdog set to reject four drugs for kidney cancer on the NHS.

Author

O'Dowd A

Subjects
Antibodies, Monoclonal economics, Antibodies, Monoclonal, Humanized, Antineoplastic Agents therapeutic use, Benzenesulfonates economics, Bevacizumab, Drug Approval economics, Drug Costs, Humans, Indoles economics, Kidney Neoplasms economics, Niacinamide analogs & derivatives, Phenylurea Compounds, Pyridines economics, Pyrroles economics, Sirolimus analogs & derivatives, Sirolimus economics, Sorafenib, State Medicine economics, Sunitinib, United Kingdom, Antineoplastic Agents economics, Kidney Neoplasms drug therapy
Published
2008
Full Text
View/download PDF

21. How much will Herceptin really cost?

Author

Barrett A, Roques T, Small M, and Smith RD

Subjects
Antibodies, Monoclonal therapeutic use, Antibodies, Monoclonal, Humanized, Antineoplastic Agents therapeutic use, Breast Neoplasms economics, Chemotherapy, Adjuvant economics, Cost-Benefit Analysis, Drug Costs, Female, Humans, Trastuzumab, Antibodies, Monoclonal economics, Antineoplastic Agents economics, Breast Neoplasms drug therapy
Published
2006
Full Text
View/download PDF

26. Prevention of respiratory syncytial virus infection in infants.

Author

Handforth J, Sharland M, and Friedland JS

Subjects
Antibodies, Monoclonal economics, Antibodies, Monoclonal, Humanized, Antiviral Agents economics, Child, Preschool, Humans, Infant, Palivizumab, Respiratory Syncytial Virus, Human immunology, Viral Vaccines immunology, Antibodies, Monoclonal therapeutic use, Antiviral Agents therapeutic use, Respiratory Syncytial Virus Infections prevention & control
Published
2004
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results